

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer: **Hydromer, Inc**

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: **35 Industrial Pkwy**

Address 2: **Branchburg, NJ 08876**

Phone: **(908)722-5000**

Website(s): **www.hydromer.com**

IR Contact: **Robert Y. Lee, CFO**

Email: **r.lee@hydromer.com**

3) Security Information

Trading Symbol: **HYDI**

Exact title and class of securities outstanding: **Common Stock**

CUSIP: **449001106**

Par or Stated Value: **no par**

Total shares authorized: **15,000,000**

as of: **12/31/16**

Total shares outstanding: **4,772,318**

as of: **12/31/16**

Additional class of securities (if necessary): **none**

Transfer Agent

Name: **Computershare Shareholder Services**

Address 1: **PO Box 30170**

Address 2: **College Station, TX 77842**

Phone: **(877) 373-6374**

Is the Transfer Agent registered under the Exchange Act? **Yes**

List any restrictions on the transfer of security: **Rule 144 restrictions**

Describe any trading suspension orders issued by the SEC in the past 12 months. **none**

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: **none**

4) Issuance History **none in past two fiscal years**

5) Financial Statements **uploaded already**

6) Issuer's Business, Products and Services

A. a description of the issuer's business operations;

Hydromer is an innovative technology-focused ISO 9001:2015 company engaged in the business of inventing, developing, patenting, licensing, manufacturing and selling hydrophilic polymer based products for commercial markets. Hydromer also provides highly specialized medical coating services to industry through its FDA registered and ISO 13485:2003 certified Biosearch Medical Products subsidiary.

The goal of Hydromer is to be the leading provider of hydrophilic surface modifications and specialty hydrophilic polymers to industry. While maintaining its industry leadership position in permanent lubricious coatings for medical devices, Hydromer constantly strives to create new, value added technologies and to build upon its current technologies – successfully expanding its technology and product base to include drug delivery and infection resistant coatings, anti-fog and condensation control coatings for optical plastics and packaging, water resistant film formers for cosmetics, pharmaceutical and animal health products, unique hydrogels for medical, bio-surgical and cosmetic applications, and barrier films for the protection of skin from allergens.

B. Date and State (or Jurisdiction) of Incorporation: **1980 New Jersey**

C. the issuer's primary and secondary SIC Codes; **6794, 2899, 3841**

D. the issuer's fiscal year end date; **June 30**

E. principal products or services, and their markets;

The Company sells polymeric complexes for commercial use in the medical, commercial, cosmetics and animal health markets.

It offers hydrophilic lubricious coatings, biostatic/anti-microbial coatings, cell anti-mitosis and anti-thrombogenic coatings and cell adhesion promoting coatings to the medical device industry primarily under the Hydromer® tradename.

For the commercial markets, the Company has Anti-Fog/Condensation Control/Anti-Frost coatings which are optically clear coatings that prevent the accumulation of vision-obscuring condensation under high humidity conditions. The Company is selling this material to manufacturers of greenhouse panels, refrigerator freezer doors, industrial and medical safety and swim goggles, aircraft windows, automotive headlight assemblies and gauge and meter manufacturers in the U.S. and internationally.

The Aquamere® series of the Company's cosmetic intermediaries, a cosmetic intermediate with water resistant film forming properties, are sold to major cosmetic companies worldwide for use in hair dyes, hair conditioners, mascaras, eye shadows, sunscreens and body lotions. They are currently in test for use in shampoos, hair styling aids and for OTC dermal drug delivery.

In the Animal Health market, the Company offers T-HEXX® barrier teat dip products/additives for the prevention of mastitis in dairy animals and DRAGONHYDE® hoof enhancement products.

The Company owns various trademarks, including AQUAMERE®, AQUATRIX® cosmetic hydrogels; BIOSEARCH® medical devices; CARVANELLA®, a triclosan free herbal dairy cleaner, DERMASEAL® dermal barrier film product for the prevention of contact dermatitis; DRAGONHYDE®, hoof enhancement products; HERBADIP®, a low-drip post-milking barrier teat dip, HYDROMER® hydrophilic and hydrophobic coatings; SEA-SLIDE® coating for watercraft hulls; and T-HEXX®.

7) Describe the Issuer's Facilities

The Company's sole facility is located at 35 Industrial Parkway, Branchburg, NJ and is secured by a mortgage through a bank. The property is in good condition.

8) **Officers, Directors, and Control Persons**

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Executive Officers

Manfred F. Dyck Chairman of the Board, Chief Executive Officer and President

Martin C. Dyck Executive Vice-President, Operations and

President Biosearch Medical Products subsidiary

John Konar Vice-President, Quality Assurance and Director of Human Resources

Robert Y. Lee Vice-President, Finance, Chief Financial Officer and Treasurer

Directors

MANFRED F. DYCK

DIETER HEINEMANN

ROBERT H. BEA

ARTHUR K. DEGEN

JAMES S. PACETTI

MICHAEL F. RYAN, Ph.D.

GEORGE A. ZIETS

Security Ownership of Management

<u>Name</u>	<u>Shares</u>	<u>%</u>
MANFRED F. DYCK	1,618,376	33.9%
DIETER HEINEMANN	814,000	17.1%
ROBERT H. BEA	10,000	Less than 1%
ARTHUR K. DEGEN	4,000	Less than 1%

- B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of: **n/a: none**

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); **none**
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; **none**
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or **none**
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities. **none**

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

<u>Name</u>	<u>Shares</u>	<u>%</u>
MANFRED F. DYCK 255 Holland Road Far Hills, NJ 07931	1,618,376	33.9%
DIETER HEINEMANN Goldbergweg 6460599 Frankfurt AM Federal Republic of Germany	814,000	17.1%

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: **Steven L. Wasserman**

Firm: **Sills Cummis & Gross P.C.**

Address 1: **30 Rockefeller Plaza**

Address 2: **New York, New York 10112**

Phone: **(973)286-5509**

Email: **swasserman@sillscummis.com**

Accountant or Auditor

Name: **Howard Condo**

Firm: **Rosenberg Rich Baker Berman**

Address 1: **265 Davidson Ave.**

Address 2: **Somerset, NJ 08873**

Phone: **(908)231-1000**

Email: **hcondo@rrbb.com**

Investor Relations Consultant **none**

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement. **none**

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Manfred F. Dyck and Robert Y. Lee certify that:

1. I have reviewed this December 2016 Disclosure of Hydromer, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 14, 2017



Manfred F. Dyck
President & Chief Executive Officer

(Digital Signatures should appear as "/s/ [OFFICER NAME]")



Robert Y. Lee
Chief Financial Officer